Big Pharma's Competitive Race for Biotech Assets Amid Patent Cliff

The pharmaceutical industry is currently experiencing a surge in mergers and acquisitions (M&A) driven by an impending "patent cliff," which threatens to strip major companies of exclusivity on blockbuster drugs. By 2032, the loss of exclusivity for leading medications, including Bristol Myers Squibb's Eliquis, Merck's Keytruda, and Novo Nordisk's Ozempic, is projected to result in a revenue loss of at least $173.9 billion annually, with some estimates reaching as high as $350 billion. This situation has prompted Big Pharma to aggressively seek new assets to replenish their pipelines, particularly in the biotech sector, which has seen a revival after a downturn in valuations post-COVID-19.

CNBC

A notable example of this competitive environment is the recent bidding war between Pfizer and Novo Nordisk for the clinical-stage weight loss drug maker Metsera, culminating in Pfizer's acquisition for up to $10 billion. This public contest highlights the urgency among pharmaceutical companies to secure promising assets as they face the imminent loss of patent protections. According to Stefan Loren, managing director at Oppenheimer, such public bidding is rare and reflects the strategic necessity for companies to catch up in a rapidly evolving market.

CNBC

Pharmaceutical firms are increasingly relying on acquisitions to bolster their portfolios. Analysis by healthcare market researcher Joanna Sadowska indicates that approximately half of the blockbuster drugs approved between 2014 and 2023 were acquired rather than developed internally. Companies like Eli Lilly and AstraZeneca have successfully integrated multiple new medicines through acquisitions, emphasizing the importance of "bolt-on deals" that align with their therapeutic focuses. GSK's Chris Sheldon noted that while partnerships and licensing agreements are preferred for managing risk, significant acquisitions may sometimes be unavoidable.

CNBC

The biotech sector's resurgence is not limited to weight loss drugs; it encompasses various therapeutic areas, including neurology, oncology, and immunology. PitchBook researchers have identified over 120 metabolic assets in development, indicating a robust pipeline of potential M&A targets. As interest rates remain low and investor optimism grows, analysts predict that 2026 could see an acceleration in deal-making activity, driven by a clearer regulatory environment and the resolution of previous uncertainties surrounding drug pricing.

CNBC

Despite the optimism, some analysts caution that the market's expectations may be overly optimistic. Rajesh Kumar from HSBC highlighted potential risks associated with inflated margin expectations beyond 2026. The competitive nature of the current M&A landscape also raises concerns about the sustainability of valuations and the long-term viability of newly acquired assets.

CNBC

• “The reality is actually the seller often dictates that, a lot of people don't realize that,” — Chris Sheldon, Global Head of Business Development at GSK

CNBC

• “It's a very public thing to chase a company, and so you have to worry about the reputational damage: A, if you lose; B: if you get too exuberant and go to buy,” — Stefan Loren, Managing Director at Oppenheimer

CNBC

• “We see 2026 as providing one of the best investing opportunities we have seen in decades,” — PitchBook Analysts

CNBC

As the pharmaceutical industry navigates this complex landscape, the interplay between innovation, acquisition strategies, and market dynamics will shape the future of biopharma in the coming years.

CNBC